Shares of Sarepta Therapeutics Inc (NASDAQ:SRPT) have received an average rating of “Buy” from the twenty-four brokerages that are covering the stock, MarketBeat.com reports. Two investment analysts have rated the stock with a hold recommendation, twenty-one have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1 year price objective among analysts that have issued a report on the stock in the last year is $187.06.
A number of equities research analysts have weighed in on SRPT shares. Robert W. Baird cut their target price on Sarepta Therapeutics from $202.00 to $181.00 and set an “outperform” rating for the company in a research report on Tuesday, August 20th. Royal Bank of Canada set a $204.00 target price on Sarepta Therapeutics and gave the stock a “buy” rating in a research report on Tuesday, September 24th. Oppenheimer restated a “hold” rating on shares of Sarepta Therapeutics in a research report on Tuesday, October 8th. Credit Suisse Group cut their target price on Sarepta Therapeutics from $201.00 to $185.00 and set an “outperform” rating for the company in a research report on Friday, November 8th. Finally, Needham & Company LLC cut their target price on Sarepta Therapeutics from $196.00 to $170.00 and set a “buy” rating for the company in a research report on Wednesday, August 21st.
In related news, Director Michael W. Bonney acquired 2,000 shares of the business’s stock in a transaction dated Monday, September 9th. The stock was bought at an average price of $86.74 per share, for a total transaction of $173,480.00. Following the transaction, the director now owns 7,051 shares of the company’s stock, valued at $611,603.74. The purchase was disclosed in a filing with the SEC, which is available through this hyperlink. Also, Director Richard Barry acquired 5,000 shares of the business’s stock in a transaction dated Friday, September 13th. The shares were bought at an average price of $87.49 per share, with a total value of $437,450.00. Following the transaction, the director now directly owns 3,183,756 shares in the company, valued at approximately $278,546,812.44. The disclosure for this purchase can be found here. Insiders have bought a total of 9,500 shares of company stock valued at $830,880 in the last quarter. Insiders own 6.60% of the company’s stock.
SRPT traded up $0.14 during trading on Thursday, reaching $98.04. The stock had a trading volume of 1,128,500 shares, compared to its average volume of 1,372,581. The firm has a market capitalization of $7.26 billion, a price-to-earnings ratio of -17.96 and a beta of 2.19. The company has a quick ratio of 5.54, a current ratio of 6.31 and a debt-to-equity ratio of 0.49. Sarepta Therapeutics has a 1-year low of $72.05 and a 1-year high of $158.80. The stock has a 50 day moving average of $87.64 and a two-hundred day moving average of $112.35.
Sarepta Therapeutics (NASDAQ:SRPT) last released its earnings results on Thursday, November 7th. The biotechnology company reported ($1.70) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.35) by ($0.35). The firm had revenue of $99.04 million during the quarter, compared to analyst estimates of $98.49 million. Sarepta Therapeutics had a negative return on equity of 55.44% and a negative net margin of 169.87%. The business’s revenue for the quarter was up 26.2% on a year-over-year basis. During the same quarter last year, the company earned ($1.15) earnings per share. On average, research analysts forecast that Sarepta Therapeutics will post -6 EPS for the current fiscal year.
About Sarepta Therapeutics
Sarepta Therapeutics, Inc focuses on the discovery and development of RNA-based therapeutics, gene therapy, and other genetic medicine approaches for the treatment of rare diseases. The company offers EXONDYS 51, a disease-modifying therapy for duchenne muscular dystrophy (DMD). Its products pipeline include Golodirsen, a product candidate that binds to exon 53 of dystrophin pre-mRNA, which results in exclusion or skipping of exon during mRNA processing in patients with genetic mutations; and Casimersen, a product candidate that uses phosphorodiamidate morpholino oligomer (PMO) chemistry and exon-skipping technology to skip exon 45 of the DMD gene.
Read More: What is the definition of arbitrage?
Receive News & Ratings for Sarepta Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.